Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.13
CVS's Cash to Debt is ranked lower than
83% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.55 vs. CVS: 0.13 )
Ranked among companies with meaningful Cash to Debt only.
CVS' s 10-Year Cash to Debt Range
Min: 0.06   Max: 1.14
Current: 0.13

0.06
1.14
Equity to Asset 0.50
CVS's Equity to Asset is ranked higher than
71% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.36 vs. CVS: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
CVS' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.67
Current: 0.5

0.39
0.67
Interest Coverage 14.31
CVS's Interest Coverage is ranked higher than
52% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.31 vs. CVS: 14.31 )
Ranked among companies with meaningful Interest Coverage only.
CVS' s 10-Year Interest Coverage Range
Min: 8.01   Max: 29.6
Current: 14.31

8.01
29.6
F-Score: 6
Z-Score: 4.93
M-Score: -2.54
WACC vs ROIC
9.00%
11.02%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 6.23
CVS's Operating margin (%) is ranked higher than
69% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.70 vs. CVS: 6.23 )
Ranked among companies with meaningful Operating margin (%) only.
CVS' s 10-Year Operating margin (%) Range
Min: 3.46   Max: 6.91
Current: 6.23

3.46
6.91
Net-margin (%) 3.31
CVS's Net-margin (%) is ranked higher than
69% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.51 vs. CVS: 3.31 )
Ranked among companies with meaningful Net-margin (%) only.
CVS' s 10-Year Net-margin (%) Range
Min: 0.65   Max: 3.76
Current: 3.31

0.65
3.76
ROE (%) 12.50
CVS's ROE (%) is ranked higher than
70% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 8.50 vs. CVS: 12.50 )
Ranked among companies with meaningful ROE (%) only.
CVS' s 10-Year ROE (%) Range
Min: 3.69   Max: 18.7
Current: 12.5

3.69
18.7
ROA (%) 6.45
CVS's ROA (%) is ranked higher than
83% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.05 vs. CVS: 6.45 )
Ranked among companies with meaningful ROA (%) only.
CVS' s 10-Year ROA (%) Range
Min: 1.52   Max: 9.8
Current: 6.45

1.52
9.8
ROC (Joel Greenblatt) (%) 59.31
CVS's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 76.39 vs. CVS: 59.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CVS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 18.78   Max: 60.5
Current: 59.31

18.78
60.5
Revenue Growth (3Y)(%) 14.50
CVS's Revenue Growth (3Y)(%) is ranked higher than
56% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.30 vs. CVS: 14.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CVS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 7.7   Max: 16
Current: 14.5

7.7
16
EBITDA Growth (3Y)(%) 14.30
CVS's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.60 vs. CVS: 14.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CVS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 2.4   Max: 44
Current: 14.3

2.4
44
EPS Growth (3Y)(%) 15.20
CVS's EPS Growth (3Y)(%) is ranked higher than
71% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.40 vs. CVS: 15.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CVS' s 10-Year EPS Growth (3Y)(%) Range
Min: 1.4   Max: 109.5
Current: 15.2

1.4
109.5
» CVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CVS Guru Trades in Q2 2014

Paul Tudor Jones 5,542 sh (New)
Manning & Napier Advisors, Inc 133,150 sh (New)
Louis Moore Bacon 5,316 sh (New)
Joel Greenblatt 65,796 sh (+763.24%)
Tom Gayner 197,000 sh (+105.21%)
Ken Fisher 155,365 sh (+76.33%)
James Barrow 348,795 sh (+18.48%)
Bill Frels 3,402 sh (+1.04%)
RS Investment Management 607,225 sh (+0.53%)
First Pacific Advisors 7,497,100 sh (+0.35%)
Robert Olstein 92,000 sh (unchged)
Charles de Vaulx 899,866 sh (unchged)
Steven Romick 6,805,000 sh (unchged)
John Rogers 98,420 sh (unchged)
Vanguard Health Care Fund 4,388,100 sh (unchged)
Westport Asset Management 192,090 sh (unchged)
Caxton Associates 100,000 sh (unchged)
Ruane Cunniff 27,028 sh (-0.08%)
Mario Gabelli 1,563,642 sh (-0.32%)
Jeff Auxier 98,449 sh (-0.35%)
PRIMECAP Management 3,206,070 sh (-0.49%)
Pioneer Investments 4,287,706 sh (-4.99%)
Chris Davis 9,012,151 sh (-21.19%)
NWQ Managers 2,118,767 sh (-22.79%)
Scott Black 126,558 sh (-29.12%)
Jeremy Grantham 109,100 sh (-93.38%)
» More
Q3 2014

CVS Guru Trades in Q3 2014

Steven Cohen 60,300 sh (New)
Jeremy Grantham 347,800 sh (+218.79%)
Bill Frels 4,243 sh (+24.72%)
Tom Gayner 218,000 sh (+10.66%)
James Barrow 359,133 sh (+2.96%)
Charles de Vaulx 913,605 sh (+1.53%)
First Pacific Advisors 7,565,900 sh (+0.92%)
Westport Asset Management 192,090 sh (unchged)
Robert Olstein 92,000 sh (unchged)
Steven Romick 6,805,000 sh (unchged)
Vanguard Health Care Fund 4,388,100 sh (unchged)
Pioneer Investments 5,372,599 sh (unchged)
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
PRIMECAP Management 3,198,460 sh (-0.24%)
Jeff Auxier 98,124 sh (-0.33%)
Ruane Cunniff 26,553 sh (-1.76%)
Scott Black 124,326 sh (-1.76%)
Mario Gabelli 1,528,010 sh (-2.28%)
John Rogers 95,275 sh (-3.20%)
NWQ Managers 1,939,169 sh (-8.48%)
RS Investment Management 552,150 sh (-9.07%)
Manning & Napier Advisors, Inc 120,770 sh (-9.30%)
Ken Fisher 140,754 sh (-9.40%)
Signature Select Canadian Fund 99,853 sh (-20.78%)
Chris Davis 2,153,905 sh (-76.10%)
Joel Greenblatt 9,348 sh (-85.79%)
» More
Q4 2014

CVS Guru Trades in Q4 2014

Paul Tudor Jones 11,847 sh (New)
Ray Dalio 55,411 sh (New)
Tom Gayner 232,000 sh (+6.42%)
Manning & Napier Advisors, Inc 125,196 sh (+3.66%)
Pioneer Investments 5,496,034 sh (+2.30%)
Ken Fisher 142,036 sh (+0.91%)
Charles de Vaulx 915,821 sh (+0.24%)
Westport Asset Management 192,090 sh (unchged)
Chris Davis Sold Out
Steven Cohen Sold Out
Jeff Auxier 97,799 sh (-0.33%)
PRIMECAP Management 3,186,930 sh (-0.36%)
John Rogers 93,675 sh (-1.68%)
James Barrow 352,989 sh (-1.71%)
Mario Gabelli 1,489,263 sh (-2.54%)
Ruane Cunniff 24,953 sh (-6.03%)
Vanguard Health Care Fund 4,015,136 sh (-8.50%)
Steven Romick 6,220,000 sh (-8.60%)
First Pacific Advisors 6,885,500 sh (-8.99%)
RS Investment Management 496,750 sh (-10.03%)
Bill Frels 3,731 sh (-12.07%)
Scott Black 108,124 sh (-13.03%)
Robert Olstein 75,000 sh (-18.48%)
NWQ Managers 1,287,296 sh (-33.62%)
Jeremy Grantham 226,300 sh (-34.93%)
Joel Greenblatt 5,154 sh (-44.87%)
» More
Q1 2015

CVS Guru Trades in Q1 2015

Caxton Associates 4,000 sh (New)
Richard Pzena 527,165 sh (New)
Joel Greenblatt 272,287 sh (+5183.02%)
Paul Tudor Jones 94,783 sh (+700.06%)
Jeremy Grantham 1,049,025 sh (+363.56%)
Manning & Napier Advisors, Inc 141,000 sh (+12.62%)
Ken Fisher 158,975 sh (+11.93%)
Tom Gayner 245,000 sh (+5.60%)
PRIMECAP Management 3,303,890 sh (+3.67%)
Charles de Vaulx 915,821 sh (unchged)
Westport Asset Management 192,090 sh (unchged)
Ruane Cunniff 24,953 sh (unchged)
Bill Frels Sold Out
Ray Dalio Sold Out
Pioneer Investments 5,446,829 sh (-0.90%)
Vanguard Health Care Fund 3,899,920 sh (-2.87%)
Mario Gabelli 1,438,163 sh (-3.43%)
RS Investment Management 478,044 sh (-3.77%)
Scott Black 100,312 sh (-7.23%)
NWQ Managers 1,173,665 sh (-8.83%)
John Rogers 84,095 sh (-10.23%)
James Barrow 304,950 sh (-13.61%)
Robert Olstein 57,000 sh (-24.00%)
First Pacific Advisors 4,629,500 sh (-32.76%)
Steven Romick 4,146,600 sh (-33.33%)
Jeff Auxier 45,209 sh (-53.77%)
» More
» Details

Insider Trades

Latest Guru Trades with CVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on CVS Health Corp

Mario Gabelli Comments on CVS Health Corp - Mar 12, 2015

CVS Health Corp. (0.9%) (CVS – $96.31 – NYSE) is a pharmacy innovation company helping people on their path to better health. Through their 7,800 retail pharmacies, more than 900 walk-in medical clinics, a leading pharmacy benefits manager with nearly 65 million plan members, and expanding specialty pharmacy services, CVS Health enables people, businesses and communities to manage health in more affordable, effective ways. Their unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs.

From Mario Gabelli (Trades, Portfolio)’s Asset Fund Q4 2014 Commentary.

Check out Mario Gabelli latest stock trades

Mario Gabelli Comments on CVS Health Corp - Oct 29, 2014

CVS Health Corp. (1.6%) (CVS - $79.59 - NYSE) operates one of the largest retail pharmacy chains in the country, and the company is poised to benefit from the expansion of insurance coverage under healthcare reform with no new taxes or regulation. CVS is expanding into the fast growing market for specialty and biotech medicines, particularly through the recently announced $2 billion acquisition of home infusion provider Coram. CVS Health recently stopped selling tobacco in its stores, but the company is performing so strongly this year that it can easily absorb the $2 billion in lost sales. The company can sustain double digit earnings growth, and management continues to return a substantial amount of cash to shareholders via a higher dividend and share repurchases.

From Mario Gabelli (Trades, Portfolio)’s Equity Income Fund Q3 2014 Commentary.

Check out Mario Gabelli latest stock trades

Jeff Auxier Comments on CVS - Feb 13, 2014

Healthcare stocks in the Fund had a strong fourth quarter and year. CVS (CVS)’s 26% performance for the quarter is reflective of the fact that 10,000 Americans turn 65 every day and will for the next 15 years. Businesses that are able to serve this growing segment with improving service, innovation, technology, product quality and value should continue to win.



From Jeff Auxier (Trades, Portfolio)'s fourth quarter 2013 commentary.

Check out Jeff Auxier latest stock trades

Top Ranked Articles about CVS Health Corp

Richard Pzena Makes 12 New Buys in First Quarter
Guru Richard Pzena (Trades, Portfolio), founder and co-chief investment officer of Pzena Investment Management, LLC, made both his reputation and his fortune by focusing on good companies selling at low prices. In the first quarter of 2015, the emphasis in Pzena’s 12 new buys was clearly on technology companies, energy stocks and financial services – but not exclusively. Read more...
Mario Gabelli Comments on CVS Health Corp
CVS Health Corp. (0.9%) (CVS – $96.31 – NYSE) is a pharmacy innovation company helping people on their path to better health. Through their 7,800 retail pharmacies, more than 900 walk-in medical clinics, a leading pharmacy benefits manager with nearly 65 million plan members, and expanding specialty pharmacy services, CVS Health enables people, businesses and communities to manage health in more affordable, effective ways. Their unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Read more...
Oakmark Equity and Income Fund Fourth Quarter 2014 Commentary
Another strong December, quarter and year Read more...
Mario Gabelli Comments on CVS Health Corp
CVS Health Corp. (1.6%) (CVS - $79.59 - NYSE) operates one of the largest retail pharmacy chains in the country, and the company is poised to benefit from the expansion of insurance coverage under healthcare reform with no new taxes or regulation. CVS is expanding into the fast growing market for specialty and biotech medicines, particularly through the recently announced $2 billion acquisition of home infusion provider Coram. CVS Health recently stopped selling tobacco in its stores, but the company is performing so strongly this year that it can easily absorb the $2 billion in lost sales. The company can sustain double digit earnings growth, and management continues to return a substantial amount of cash to shareholders via a higher dividend and share repurchases. Read more...
The Olstein All Cap Value Fund’s 2014 First Quarter Letter to Shareholders
Dear Fellow Shareholders: Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.20
CVS's P/E(ttm) is ranked higher than
61% of the 31 Companies
in the Global Health Care Plans industry.

( Industry Median: 30.50 vs. CVS: 25.20 )
Ranked among companies with meaningful P/E(ttm) only.
CVS' s 10-Year P/E(ttm) Range
Min: 10.57   Max: 26.1
Current: 25.2

10.57
26.1
Forward P/E 17.57
CVS's Forward P/E is ranked lower than
69% of the 36 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.95 vs. CVS: 17.57 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.40
CVS's PE(NRI) is ranked higher than
61% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 29.10 vs. CVS: 25.40 )
Ranked among companies with meaningful PE(NRI) only.
CVS' s 10-Year PE(NRI) Range
Min: 10.58   Max: 26.1
Current: 25.4

10.58
26.1
P/B 3.20
CVS's P/B is ranked lower than
65% of the 37 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.70 vs. CVS: 3.20 )
Ranked among companies with meaningful P/B only.
CVS' s 10-Year P/B Range
Min: 1.01   Max: 3.37
Current: 3.2

1.01
3.37
P/S 0.80
CVS's P/S is ranked lower than
100% of the 36 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.52 vs. CVS: 0.80 )
Ranked among companies with meaningful P/S only.
CVS' s 10-Year P/S Range
Min: 0.4   Max: 0.87
Current: 0.8

0.4
0.87
PFCF 20.30
CVS's PFCF is ranked lower than
62% of the 37 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.20 vs. CVS: 20.30 )
Ranked among companies with meaningful PFCF only.
CVS' s 10-Year PFCF Range
Min: 9.1   Max: 208.79
Current: 20.3

9.1
208.79
POCF 15.09
CVS's POCF is ranked lower than
55% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.46 vs. CVS: 15.09 )
Ranked among companies with meaningful POCF only.
CVS' s 10-Year POCF Range
Min: 6.73   Max: 35.81
Current: 15.09

6.73
35.81
EV-to-EBIT 14.42
CVS's EV-to-EBIT is ranked higher than
53% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.42 vs. CVS: 14.42 )
Ranked among companies with meaningful EV-to-EBIT only.
CVS' s 10-Year EV-to-EBIT Range
Min: 7.6   Max: 20.4
Current: 14.42

7.6
20.4
PEG 2.27
CVS's PEG is ranked lower than
53% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.54 vs. CVS: 2.27 )
Ranked among companies with meaningful PEG only.
CVS' s 10-Year PEG Range
Min: 0.56   Max: 5.53
Current: 2.27

0.56
5.53
Shiller P/E 31.40
CVS's Shiller P/E is ranked lower than
58% of the 31 Companies
in the Global Health Care Plans industry.

( Industry Median: 27.37 vs. CVS: 31.40 )
Ranked among companies with meaningful Shiller P/E only.
CVS' s 10-Year Shiller P/E Range
Min: 13.89   Max: 32.87
Current: 31.4

13.89
32.87
Current Ratio 1.30
CVS's Current Ratio is ranked higher than
62% of the 24 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.07 vs. CVS: 1.30 )
Ranked among companies with meaningful Current Ratio only.
CVS' s 10-Year Current Ratio Range
Min: 1.05   Max: 2.09
Current: 1.3

1.05
2.09
Quick Ratio 0.68
CVS's Quick Ratio is ranked lower than
71% of the 24 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.92 vs. CVS: 0.68 )
Ranked among companies with meaningful Quick Ratio only.
CVS' s 10-Year Quick Ratio Range
Min: 0.2   Max: 0.93
Current: 0.68

0.2
0.93
Days Inventory 36.26
CVS's Days Inventory is ranked lower than
77% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.63 vs. CVS: 36.26 )
Ranked among companies with meaningful Days Inventory only.
CVS' s 10-Year Days Inventory Range
Min: 36.78   Max: 99.44
Current: 36.26

36.78
99.44
Days Sales Outstanding 25.94
CVS's Days Sales Outstanding is ranked lower than
54% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 24.93 vs. CVS: 25.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
CVS' s 10-Year Days Sales Outstanding Range
Min: 10.82   Max: 25.37
Current: 25.94

10.82
25.37

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.20
CVS's Dividend Yield is ranked higher than
54% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.20 vs. CVS: 1.20 )
Ranked among companies with meaningful Dividend Yield only.
CVS' s 10-Year Dividend Yield Range
Min: 0.42   Max: 1.47
Current: 1.2

0.42
1.47
Dividend Payout 0.29
CVS's Dividend Payout is ranked lower than
58% of the 12 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.20 vs. CVS: 0.29 )
Ranked among companies with meaningful Dividend Payout only.
CVS' s 10-Year Dividend Payout Range
Min: 0.08   Max: 1.87
Current: 0.29

0.08
1.87
Dividend growth (3y) 30.10
CVS's Dividend growth (3y) is ranked higher than
62% of the 8 Companies
in the Global Health Care Plans industry.

( Industry Median: 29.10 vs. CVS: 30.10 )
Ranked among companies with meaningful Dividend growth (3y) only.
CVS' s 10-Year Dividend growth (3y) Range
Min: -13.6   Max: 37
Current: 30.1

-13.6
37
Yield on cost (5-Year) 4.66
CVS's Yield on cost (5-Year) is ranked higher than
52% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.66 vs. CVS: 4.66 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
CVS' s 10-Year Yield on cost (5-Year) Range
Min: 1.63   Max: 5.71
Current: 4.66

1.63
5.71
Share Buyback Rate 4.60
CVS's Share Buyback Rate is ranked higher than
87% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: -0.60 vs. CVS: 4.60 )
Ranked among companies with meaningful Share Buyback Rate only.
CVS' s 10-Year Share Buyback Rate Range
Min: 4.6   Max: -20.4
Current: 4.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.30
CVS's Price/DCF (Projected) is ranked lower than
56% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.20 vs. CVS: 1.30 )
Ranked among companies with meaningful Price/DCF (Projected) only.
CVS' s 10-Year Price/DCF (Projected) Range
Min: 0.82   Max: 13.38
Current: 1.3

0.82
13.38
Price/Median PS Value 1.40
CVS's Price/Median PS Value is ranked lower than
84% of the 37 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.20 vs. CVS: 1.40 )
Ranked among companies with meaningful Price/Median PS Value only.
CVS' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 2.44
Current: 1.4

0.45
2.44
Price/Peter Lynch Fair Value 1.90
CVS's Price/Peter Lynch Fair Value is ranked lower than
64% of the 22 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.70 vs. CVS: 1.90 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CVS' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.63   Max: 3.68
Current: 1.9

0.63
3.68
Earnings Yield (Greenblatt) 6.90
CVS's Earnings Yield (Greenblatt) is ranked higher than
57% of the 37 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.60 vs. CVS: 6.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
CVS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.9   Max: 13.1
Current: 6.9

4.9
13.1
Forward Rate of Return (Yacktman) 16.43
CVS's Forward Rate of Return (Yacktman) is ranked lower than
65% of the 17 Companies
in the Global Health Care Plans industry.

( Industry Median: 18.45 vs. CVS: 16.43 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
CVS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.8   Max: 24.2
Current: 16.43

3.8
24.2

Business Description

Industry: Health Care Plans » Health Care Plans
Compare:SHDMF, APNHF, GNC, JCOUF, PMC » details
Traded in other countries:CVS.Germany, CVS.Mexico, CVS.Chile,
CVS Health Corp, formerly known as CVS Caremark Corporation was incorporated in the State of Delaware. The Company is an integrated pharmacy health care provider in the United States. They have three segments: Pharmacy Services, Retail Pharmacy and Corporate. The pharmacy services segment provides pharmacy benefit management services, as described more fully below, to their clients consisting primarily of employers, insurance companies, unions, government employee groups, managed care organizations ("MCOs") and other sponsors of health benefit plans and individuals throughout the United States. They operate a network of mail service specialty pharmacies. There specialty pharmacies were comprised of 11 specialty mail order pharmacies located throughout the United States that are used for delivery of medications to individuals with chronic or genetic diseases and disorders. The retail pharmacy segment included 7,660 retail drugstores, of which 7,603 operated a pharmacy, their online retail pharmacy websites, CVS.com and Onofre.com.br, 17 onsite pharmacy stores and retail health care clinics. There corporate segment provides management and administrative services to support the operations of the company. The corporate Segment consists of certain aspects of executive management, corporate relations, legal, compliance, human resources, corporate information technology and finance departments. Its customers include managed care organizations and government-funded health care commercial employers. It competes with other drugstore chains like Walgreens and Rite Aid, supermarkets, discount retailers (e.g., Wal-Mart and Target), independent pharmacies, restrictive pharmacy networks, membership clubs, Internet companies and retail health clinics, as well as other mail order pharmacies and PBMs. The Company's business is subject to federal and state laws and regulations that govern the purchase, sale and distribution of prescription drugs and related services, including administration and management of prescription drug benefits.
» More Articles for CVS

Headlines

Articles On GuruFocus.com
CVS Eyeing Omnicare Acquisition To Bolster Market Position May 23 2015 
Mario Gabelli’s Asset Fund Q1 2015 Commentary May 22 2015 
CVS To Buy Out Omnicare For $10.4 Billion May 22 2015 
Glenview Capital Raises Stake In Monsanto May 21 2015 
Compass Capital Management's Top 3 Picks During Q1 May 11 2015 
Richard Pzena Makes 12 New Buys in First Quarter May 11 2015 
Steven Romick's FPA Crescent Fund First Quarter 2015 Commentary May 06 2015 
6 Dividend Stocks Trading at a Double-Digit Discount Apr 22 2015 
Rite Aid Posts Impressive Q4 Results But Disappointing 2016 Guidance Apr 10 2015 
CVS Health Corporation (CVS) Dividend Stock Analysis Apr 07 2015 

More From Other Websites
Is CVS Health (CVS) Worth Adding to Your Portfolio Now? - Analyst Blog May 29 2015
Top trades to go before the closing bell May 27 2015
Will Rite Aid Ever Catch CVS Health? May 26 2015
OMNICARE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC... May 26 2015
Canaccord Reiterates On Alere, Boosts Price Target To $60 May 26 2015
CVS Deal for Omnicare Seen Avoiding PharMerica Antitrust Stumble May 26 2015
Five things you need to know today, and do I need satellite TV? May 26 2015
CFOs Seek to Avoid Bite of Health Law's 'Cadillac Tax' May 26 2015
[$$] CFOs Seek to Avoid Bite of Health Law’s ‘Cadillac Tax’ May 25 2015
Was CVS' cigarettes decision the right one? May 24 2015
Follow Up May 22 2015
Saluting the Monster Wave in Health Care Mergers and Recognizing Signs of a True Recovery: Jim... May 22 2015
CVS HEALTH CORP Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial... May 22 2015
WeissLaw LLP: Omnicare, Inc. Acquisition by CVS Health Corporation May Not be In The Best Interest... May 22 2015
CVS Health to Buy Omnicare for $12.7B; Eyes Specialty Care - Analyst Blog May 22 2015
Here’s What Happened After CVS Stopped Selling Cigarettes May 22 2015
12 Worst Buys in Funds May 22 2015
The word is this company could be the target of the next big healthcare deal — and now the stock... May 22 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Omnicare Inc. of Commencement of... May 22 2015
CVS Health (CVS) Stock Price Target Increased by Analysts May 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK